The shares are up $1.54 to $19.36 in afternoon trading with Elevidys remaining on the market in the U.S.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- FDA approves new safety warning and revised indication for Sarepta’s Elevidys
- FDA appoints Richard Pazdur as Director of CDER
- Wave Life Sciences price target lowered to $16 from $18 at Wells Fargo
- Sarepta price target lowered to $20 from $22 at Barclays
- Sarepta upgraded to Outperform from Neutral at Mizuho